| Literature DB >> 27459240 |
Louise A Metherell1, José Afonso Guerra-Assunção2, Michael J Sternberg3, Alessia David4.
Abstract
Defective mitochondrial proteins are emerging as major contributors to human disease. Nicotinamide nucleotide transhydrogenase (NNT), a widely expressed mitochondrial protein, has a crucial role in the defence against oxidative stress. NNT variations have recently been reported in patients with familial glucocorticoid deficiency (FGD) and in patients with heart failure. Moreover, knockout animal models suggest that NNT has a major role in diabetes mellitus and obesity. In this study, we used experimental structures of bacterial transhydrogenases to generate a structural model of human NNT (H-NNT). Structure-based analysis allowed the identification of H-NNT residues forming the NAD binding site, the proton canal and the large interaction site on the H-NNT dimer. In addition, we were able to identify key motifs that allow conformational changes adopted by domain III in relation to its functional status, such as the flexible linker between domains II and III and the salt bridge formed by H-NNT Arg882 and Asp830. Moreover, integration of sequence and structure data allowed us to study the structural and functional effect of deleterious amino acid substitutions causing FGD and left ventricular non-compaction cardiomyopathy. In conclusion, interpretation of the function-structure relationship of H-NNT contributes to our understanding of mitochondrial disorders.Entities:
Keywords: NNT; familial glucocorticoid deficiency; mitochondrial disease; protein structure; variations
Mesh:
Substances:
Year: 2016 PMID: 27459240 PMCID: PMC5026163 DOI: 10.1002/humu.23046
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878
PDB Files used to Generate the H‐NNT Structural Model
| PDB file | Ligand | Method | Resolution | Seq Id % | NNT domain | Organism |
|---|---|---|---|---|---|---|
| 2bru | NAD, NADP | NMR | – | 56 | I, I‐I, I‐III |
|
| 4izh | Glycerol | X‐ray | 1.8 Å | 41 | I |
|
| 4o9p (chains C‐D) | – | X‐ray | 2.89 Å | 31 | II |
|
| 1djl | NADP, sulfate ion, glycerol | X‐ray | 2.0 Å | 100 | III |
|
| 4o9u | NAD, NADP | X‐ray | 6.93 Å | 33 | Holo‐NNT |
|
Seq id %, percentage of sequence identity to H‐NNT amino acid sequence; NAD, nicotinamide‐adenine‐dinucleotide; NADP, nicotinamide‐adenine‐dinucleotide phosphate.
Figure 1A: Domain organization of H‐NNT. Domains are color‐coded (domain I in yellow, domain II in gray and domain III in green). The 14 TMs of domain II are also indicated. The position of deleterious amino acid substitutions identified in H‐NNT and described in this study is presented. The protein regions for which an experimental or homology‐derived structure is available (structural coverage) are also shown. B: Three‐dimensional model of H‐NNT homodimer (monomer A and monomer B) inserted in the inner mitochondrial membrane. The reaction catalyzed by NNT is also presented. On the right, domain III (in green) is in the up‐face orientation with the NADP(H) binding site (in magenta) oriented toward domain I (in yellow) and interacting with the NAD(H) binding site (in blue). On the left, domain III (in green) is in the face‐down orientation, with the NADP(H) binding site (in magenta) facing away from the NAD(H) binding site (in blue) and in close proximity to domain II (in gray). H‐NNT dimeric model is based on Tt‐NNT (PDB 4O9U).
Figure 2NAD binding site in H‐NNT domain I. The 3D model structure of H‐NNT was used to identify residues likely to participate in NAD binding.
Figure 3NADP ligand binding site. A: 3D structure of domain III in H‐NNT. The NADP cleft is presented in green and NADP as blue spheres. B: Schematic 2D representation of domain III residues interacting with NADP. The diagram was generated with Ligplot+ using the human structure of domain III (PDB 1djl). The bold purple bonds belong to the ligand, whereas the thin brown bonds to H‐NNT. Hydrogen bonds between H‐NNT and NADP are presented as dashed lines. H‐NNT residues making hydrophobic contact are presented as spiked arcs. C: Residues Ala1008 and Asn1009, which harbor variations p.Ala1008Pro and p.Asn1009Lys, interact with NADP. H‐NNT residues have been renumbered to follow NNT amino acid numbering reported in Uniprot. The alignment between PDB 1djl and H‐NNT Uniprot sequence is available at: http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=1djl&template=align.html&l=1.
Figure 4The predicted H‐NNT domain I interface site and amino acid substitutions causing glucocorticoid deficiency. A: Surface representation of the large interface site (in green) formed by two domain I monomers (presented in light and dark gray, respectively). The NAD binding sites, one on each monomer, are presented in orange. B: Residue His365, which harbors the p.His365Pro substitution, is a rim interface residue and is predicted to interact with Asp104 on the opposite domain I. C: Phe215, which harbors the p.Phe215Ser substitution, is a conserved interface core residue. Phe215 is predicted to form stacking interactions with Phe211 on the same chain. The name (res) and position on the NNT amino acid sequence (pos) of residues predicted to form the core and rim of dimer I interface is also presented.
Conservation Score and Prediction Scores from Three Variant Prediction Servers for H‐NNT Deleterious Amino Acid Substitutions and Rare Genetic Variations Reported in the EXAC Database
| Genetic variation | Conservation score | Most common amino acids in the alignment | SIFT | Polyphen2 | Suspect | Structural analysis | Figure |
|---|---|---|---|---|---|---|---|
| p.Arg27His | 1 | Pro(50.0%), Arg(20.0%), Thr, Lys and His (10.0%) | 0.13 T | 0.000 T | 24 T | n.a. | n.a. |
| p.Lys63Arg | 4 | Lys(77.8%), Arg(16.7%), Gln(5.6%) | 0.47 T | 0.895 Poss D | 28 T | Likely tolerated | S Fig 8A |
| p.Ser193Asn | 9 | Ser(100.0%) | 0 D | 0.754 Poss D | 60 D | Likely deleterious | S Fig 5 |
| p.Gly200Ser | 9 | Gly(100.0%) | 0.02 D | 0.252 T | 90 D | Likely deleterious | S Fig 8B |
| p.Phe215Ser | 9 | Phe(100.0%) | 0 D | 1.00 D | 47 Poss D | Likely deleterious | S Fig 8C |
| p.Asp277Tyr | 5 | Asp(77.8%), Asn(16.7%), Pro(5.6%) | 0 D | 0.686 Poss D | 62 D | n.a. | n.a. |
| p.Thr357Ala | 8 | Thr(88.9%), Ser(5.6%), Ile(5.6%) | 0 D | 0.204 T | 75 D | Likely deleterious | S Fig 8D |
| p.His365Pro | 1 | His(61.1%), Val and Lys(11.1%), Tyr, Glu and Ala(5.6%) | 0.27 T | 0.915 Poss D | 19 T | Likely deleterious | S Fig 8E |
| p.Tyr388Ser | 7 | Tyr(94.4%), Phe(5.6%) | 0 D | 1.00 D | 85 D | Likely deleterious | S Fig 8F |
| p.Pro437Leu | 7 | Pro(94.4%), Gly(5.6%) | 0 D | 0.942 Poss D | 77 D | Likely deleterious | S Fig 8G |
| p.Ala533Val | 8 | Ala(94.4%), Phe(5.6%) | 0 D | 0.986 D | 80 D | Likely deleterious | S Fig 8H |
| p.Thr589Ser | 2* | Thr(62.5%), Asp(25.0%), Gln(6.3%), Pro(6.3%) | 0.09 T | 0.376 T | 15 T | n.a. | n.a. |
| p.Leu663Phe | 5 | Gly(77.8%), Phe(11.1%), Val(5.6%), Leu(5.6%) | 0.01 D | 1.00 D | 24 T | Likely tolerated | S Fig 8I |
| p.Gly664Arg | 8 | Gly(100.0%) | 0 D | 1.00 D | 56 D | Likely deleterious | S Fig 8J |
| p.Gly678Arg | 1 | Gly(61.1%), Leu(22.2%), Thr, Ser and Ala(5.6%) | 0.02 D | 0.841 Poss D | 56 D | Likely deleterious | S Fig 8K |
| p.Thr731Met | 1 | Thr(52.9%), Glu(23.5%), Ala(11.8%), Met and Leu(5.9%) | 0.07 T | 0.035 T | 21 T | Likely tolerated | S Fig 8L |
| p.Gly862Asp | 9 | Gly(100.0%) | 0 D | 1.00 D | 87 D | Likely deleterious | S Fig 8M |
| p.Leu977Pro | 9 | Leu(100.0%) | 0 D | 1.00 D | 92 D | Likely deleterious | S Fig 8N |
| p.Ile993Val | 9 | Ile(94.4%), Leu(5.6%) | 0.04 D | 0.804 poss D | 35 T | Likely tolerated | S Fig 8O |
| p.Ala1008Pro | 9 | Ala(94.4%), Ser(5.6%) | 0 D | 1.00 D | 94 D | Likely deleterious | S Fig 8P |
| p.Asn1009Lys | 9 | Asn(100.0%) | 0 D | 1.00 D | 84 D | Likely deleterious | S Fig 8Q |
D, deleterious; Poss D, possibly deleterious; T, tolerated. Score is predicted deleterious if <0.05 for SIFT and ≥50 for Suspect. Polyphen2 calculates the naïve Bayesian posterior probability that a mutation is deleterious and classifies it accordingly, in “possibly” or “probably” deleterious or tolerated. *, unreliable estimate due to high number of gaps in alignment. S Fig, Supp. Figure.
Rare Amino Acid Substitutions Identified in Homozygosity in the 1000Genomes Project
| Protein consequence | Transcript consequence | Filter | Annotation | Allele count | Allele number | Number of homozygotes |
|---|---|---|---|---|---|---|
| p.Lys63Arg | ENST00000264663.5:c.188A > G | PASS | Missense | 5,565 | 121100 | 196 |
| p.Leu663Phe | ENST00000264663.5:c.1987C > T | PASS | Missense | 5,425 | 121298 | 188 |
| p.Ile993Val | ENST00000264663.5:c.2977A > G | PASS | Missense | 1,107 | 120944 | 7 |
| p.Thr731Met | ENST00000264663.5:c.2192C > T | PASS | Missense | 897 | 121348 | 4 |
| p.Arg27His | ENST00000264663.5:c.80G > A | PASS | Missense | 197 | 121362 | 2 |
| p.Thr589Ser | ENST00000264663.5:c.1765A > T | PASS | Missense | 17 | 121412 | 1 |